Painreform Ltd (PRFX)

$1.13 +0.31 (37.96%)
Market Cap 2.28M
Revenue (ttm) 0.00
Net Income (ttm) -14.59M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 64,154,902
Avg Vol 2,111,514
Day's Range N/A - N/A
Shares Out 2.01M
Stochastic %K 50%
Beta 0.59
Analysts Strong Buy
Price Target $47.99

Company Profile

PRF Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on the reformulation of established therapeutics and provides an extended period of post-surgical pain relief in Israel. It develops PRF-110, a viscous clear oil-based solution that is instilled directly into the surgical wound to provide localized and extended post-operative analgesia, as well as in Phase 3 clinical trial for pain treatment of patients undergoing bunionectomy and pain treatment of hernia repair op...

Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Phone: 972 3 7177050
Address:
65 Yigal Alon St., Tel Aviv-Yafo, Israel
XZerolag
XZerolag Apr. 27 at 8:17 PM
$FCUV $EDHL $RLYB $PRFX east
0 · Reply
SA449
SA449 Apr. 27 at 5:29 PM
$PRFX always be optimistic
0 · Reply
Unalloyed
Unalloyed Apr. 27 at 2:06 PM
$PRFX
0 · Reply
Unalloyed
Unalloyed Apr. 27 at 2:05 PM
$PRFX
0 · Reply
SA449
SA449 Apr. 24 at 6:54 AM
$PRFX
0 · Reply
ricraeli
ricraeli Apr. 24 at 6:18 AM
For 04/24 $PRFX $EDBL $LVLU
0 · Reply
SA449
SA449 Apr. 23 at 12:36 PM
$PRFX always be optimistic
0 · Reply
BiotechGoldenEra
BiotechGoldenEra Apr. 16 at 2:46 AM
$PRFX go bunions
0 · Reply
_Sensei_
_Sensei_ Apr. 10 at 9:22 PM
$RAYA $REBN $PRFX $SPY Top plays of the week! RAYA was the highlight! Guys, Stop missing runners. See you all next week 🌊
0 · Reply
TommyDel
TommyDel Apr. 9 at 6:34 PM
$AIKI.X $PRFX $AIXI
0 · Reply
Latest News on PRFX
PRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar Platforms

Mar 27, 2026, 8:00 AM EDT - 4 weeks ago

PRF Technologies Provides Year-End 2025 Business Update Highlighting Strategic Progress Across Healthcare and AI-Driven Solar Platforms

PRF Technologies Ltd. Announces Commercial Collaboration Agreement with Blade Ranger to Accelerate Large-Scale DeepSolar Commercial Engagements

Mar 17, 2026, 8:30 AM EDT - 5 weeks ago

PRF Technologies Ltd. Announces Commercial Collaboration Agreement with Blade Ranger to Accelerate Large-Scale DeepSolar Commercial Engagements

PRF Technologies' DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable Energy

Feb 18, 2026, 9:15 AM EST - 2 months ago

PRF Technologies' DeepSolar Announces its First Commercial Due Diligence Engagement with EDF Power Solutions Israel, a Global Leader in Renewable Energy

PRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar's Installed Commercial Base

Feb 11, 2026, 8:30 AM EST - 2 months ago

PRF Technologies Wins Another European Utility-Scale Solar Deployment, Expanding DeepSolar's Installed Commercial Base

PRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast Accuracy

Jan 20, 2026, 9:05 AM EST - 3 months ago

PRF Technologies Files Its First Patent Application for Solar Plant Micro-Climate Forecast Modeling Designed to Improve Energy Production Forecast Accuracy

PainReform Stock Spikes As It Rebrands, Expands Beyond Pharma With AI, Clean Energy Push

Jan 16, 2026, 11:39 AM EST - 3 months ago

PainReform Stock Spikes As It Rebrands, Expands Beyond Pharma With AI, Clean Energy Push

PainReform Ltd. Changes Name to PRF Technologies Ltd.

Jan 15, 2026, 4:05 PM EST - 3 months ago

PainReform Ltd. Changes Name to PRF Technologies Ltd.

PainReform's LayerBio's Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies

Jan 12, 2026, 9:00 AM EST - 3 months ago

PainReform's LayerBio's Drop-Less OcuRing™-K Delivery Platform Demonstrates Favorable Safety Profile in Preclinical and Phase I Clinical Studies

PainReform's DeepSolar Launches Smart TDD, a Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A Market

Jan 5, 2026, 9:00 AM EST - 4 months ago

PainReform's DeepSolar Launches Smart TDD, a Next-Generation Solar Due Diligence Service Targeting the $60B+ Global Solar Asset M&A Market

BladeRanger to Showcase Advanced Green Energy Technologies at Abu Dhabi Sustainability Week

Dec 30, 2025, 8:48 AM EST - 4 months ago

BladeRanger to Showcase Advanced Green Energy Technologies at Abu Dhabi Sustainability Week

PainReform Confirms the Ability of Its LayerBio Drop-Less Sustained-Release Ocular Platform to Accommodate Multiple Drug Entities

Dec 10, 2025, 8:30 AM EST - 4 months ago

PainReform Confirms the Ability of Its LayerBio Drop-Less Sustained-Release Ocular Platform to Accommodate Multiple Drug Entities

PainReform Commences Development for OcuRing™-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular Therapy

Dec 2, 2025, 9:15 AM EST - 5 months ago

PainReform Commences Development for OcuRing™-K Phase II Trial, LayerBio's Drop-Less Sustained-Release Ocular Therapy

PainReform's DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset Analysis

Nov 12, 2025, 9:00 AM EST - 5 months ago

PainReform's DeepSolar Advances Development of its AI-Driven Automated Reporting Engine for Solar-Asset Analysis

PainReform's DeepSolar, Developing “DeepSolar Predict” within the NVIDIA Connect Program, Featured in The Market Link's “Watchlist Interview” and Announces Progress Toward Pilot Projects

Nov 5, 2025, 8:30 AM EST - 6 months ago

PainReform's DeepSolar, Developing “DeepSolar Predict” within the NVIDIA Connect Program, Featured in The Market Link's “Watchlist Interview” and Announces Progress Toward Pilot Projects

PainReform Provides Business Update for the Six Months Ended June 30, 2025

Oct 1, 2025, 9:27 AM EDT - 7 months ago

PainReform Provides Business Update for the Six Months Ended June 30, 2025

PainReform/DeepSolar Accepted into NVIDIA Connect Program

Aug 19, 2025, 8:30 AM EDT - 8 months ago

PainReform/DeepSolar Accepted into NVIDIA Connect Program

PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System

Aug 13, 2025, 8:30 AM EDT - 9 months ago

PainReform Ltd. Completes Strategic Investment in LayerBio to Enter $9B Global Cataract Surgery Market with Breakthrough Non-Opiate, Non-Steroidal Postoperative NSAID Drug Delivery System

PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio

Jul 10, 2025, 8:30 AM EDT - 10 months ago

PainReform Ltd. enters into a Strategic Investment Agreement to Expand its Non-Opiate Pain Management Pipeline into Opthamology with LayerBio

Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales

May 27, 2025, 12:12 PM EDT - 11 months ago

Blade Ranger: Consideration from PainReform Transaction Continues to Mature Following Growth in Software Sales

PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar Projects

May 7, 2025, 4:30 PM EDT - 1 year ago

PainReform Launches Strategic AI Pilot with Econergy Using Its Proprietary DeepSolar™ Platform to Optimize One of Romania's Largest Solar Projects

PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market

Apr 10, 2025, 8:30 AM EDT - 1 year ago

PainReform Expands into Home Energy Management Sector, Leveraging DeepSolar's AI-Driven Platform to Address the Growing Solar Optimization Market

PainReform Provides Year-End Business Update

Apr 7, 2025, 5:00 PM EDT - 1 year ago

PainReform Provides Year-End Business Update

PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics

Mar 5, 2025, 11:00 AM EST - 1 year ago

PainReform Completes Strategic Acquisition of DeepSolar, Unlocking New Growth Opportunities in AI-Driven Solar Analytics

PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity

Feb 18, 2025, 8:30 AM EST - 1 year ago

PainReform Executes Definitive Agreement to Acquire DeepSolar, Marking a Unique Expansion Opportunity

PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110

Dec 27, 2024, 8:30 AM EST - 1 year ago

PainReform Provides Further Update on Phase 3 Clinical Trial of PRF-110

PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial

Nov 20, 2024, 8:30 AM EST - 1 year ago

PainReform Announces Initial Topline Data for PRF-110 Phase 3 Clinical Trial

PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

Nov 7, 2024, 5:00 PM EST - 1 year ago

PainReform Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders' Equity Requirement

PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110

Sep 11, 2024, 8:30 AM EDT - 1 year ago

PainReform Ltd. Confirms Sutures Compatibility in Human Clinical Trials for PRF-110

PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds

Sep 10, 2024, 9:46 AM EDT - 1 year ago

PainReform Announces Exercise of Warrants for $1.58 Million Gross Proceeds

PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study

Aug 20, 2024, 8:30 AM EDT - 1 year ago

PainReform Announces Positive Safety Profile for PRF-110 in Phase 3 Bunionectomy Study

PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses

Aug 7, 2024, 10:00 AM EDT - 1 year ago

PainReform Announces Favorable Safety Profile of PRF-110, Indicating Potential for Use in New Surgical Applications Requiring Higher Doses

PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature

Aug 1, 2024, 8:30 AM EDT - 1 year ago

PainReform's New Manufacturing Process Achieves Significant Benefits Including 18-Month Stability of PRF-110 at Room Temperature

PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification

May 31, 2024, 4:15 PM EDT - 2 years ago

PainReform Announces Receipt of Nasdaq Minimum Bid Price Notification

PainReform Provides Business Update for the First Quarter of 2024

May 15, 2024, 4:05 PM EDT - 2 years ago

PainReform Provides Business Update for the First Quarter of 2024

PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com

May 8, 2024, 8:30 AM EDT - 2 years ago

PainReform CEO Ilan Hadar Discusses Latest Developments Related to PRF-110 and its Potential to Help Tackle the Opioid Epidemic on Proactiveinvestors.com

PainReform Announces Closing of $4 Million Public Offering

Apr 18, 2024, 2:19 PM EDT - 2 years ago

PainReform Announces Closing of $4 Million Public Offering

PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions

Apr 9, 2024, 9:00 AM EDT - 2 years ago

PainReform's Non-Opiate Topical Treatment for Post-Surgical Pain Relief Outperforms Leading Competitor Under Various Testing Conditions

PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy

Apr 2, 2024, 8:30 AM EDT - 2 years ago

PainReform Reaches 50% Enrollment in the Second Part of its Phase 3 Clinical Trial of PRF-110 in Bunionectomy

PainReform to Present at the Microcap Conference in Atlantic City

Jan 22, 2024, 8:30 AM EST - 2 years ago

PainReform to Present at the Microcap Conference in Atlantic City

PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief

Jan 3, 2024, 8:30 AM EST - 2 years ago

PainReform Reports Successful Head-to-Head Comparison of PRF-110 Versus Market Leading Post Surgical Analgesia for Extended Postoperative Pain Relief

PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds

Dec 26, 2023, 6:00 PM EST - 2 years ago

PainReform Announces Exercise of Warrants for Approximately $1.3 Million in Gross Proceeds

PainReform Provides Business Update for the Third Quarter of 2023

Nov 15, 2023, 4:05 PM EST - 2 years ago

PainReform Provides Business Update for the Third Quarter of 2023

PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File

Sep 11, 2023, 8:30 AM EDT - 2 years ago

PainReform Announces Plans to Commence Second Part of Phase 3 Clinical Trial to Evaluate PRF-110 in Patients Undergoing Bunionectomy Surgery Following Positive FDA Review of Drug Master File

PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary

Sep 7, 2023, 10:00 AM EDT - 2 years ago

PainReform Selected for Poster Presentation at the 13th Congress of the European Pain Federation in Budapest, Hungary

PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City

Sep 5, 2023, 8:30 AM EDT - 2 years ago

PainReform to Participate in the H.C. Wainwright 25th Annual Global Investment Conference in New York City

PainReform Provides Business Update for the Second Quarter of 2023

Aug 10, 2023, 4:05 PM EDT - 2 years ago

PainReform Provides Business Update for the Second Quarter of 2023

PainReform Regains Compliance with Nasdaq Continued Listing Requirements

Jul 19, 2023, 9:00 AM EDT - 3 years ago

PainReform Regains Compliance with Nasdaq Continued Listing Requirements

PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement

Jul 14, 2023, 2:35 PM EDT - 3 years ago

PainReform Announces Pricing of $1.5 Million Concurrent Registered Direct Offering and Private Placement

PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement

Jul 12, 2023, 9:05 AM EDT - 3 years ago

PainReform Announces Pricing of $2.7 Million Concurrent Registered Direct Offering and Private Placement

PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st

Jun 15, 2023, 8:30 AM EDT - 3 years ago

PainReform to Present at the Maxim Group Virtual Healthcare Conference Hosted by M-Vest on June 21st

XZerolag
XZerolag Apr. 27 at 8:17 PM
$FCUV $EDHL $RLYB $PRFX east
0 · Reply
SA449
SA449 Apr. 27 at 5:29 PM
$PRFX always be optimistic
0 · Reply
Unalloyed
Unalloyed Apr. 27 at 2:06 PM
$PRFX
0 · Reply
Unalloyed
Unalloyed Apr. 27 at 2:05 PM
$PRFX
0 · Reply
SA449
SA449 Apr. 24 at 6:54 AM
$PRFX
0 · Reply
ricraeli
ricraeli Apr. 24 at 6:18 AM
For 04/24 $PRFX $EDBL $LVLU
0 · Reply
SA449
SA449 Apr. 23 at 12:36 PM
$PRFX always be optimistic
0 · Reply
BiotechGoldenEra
BiotechGoldenEra Apr. 16 at 2:46 AM
$PRFX go bunions
0 · Reply
_Sensei_
_Sensei_ Apr. 10 at 9:22 PM
$RAYA $REBN $PRFX $SPY Top plays of the week! RAYA was the highlight! Guys, Stop missing runners. See you all next week 🌊
0 · Reply
TommyDel
TommyDel Apr. 9 at 6:34 PM
$AIKI.X $PRFX $AIXI
0 · Reply
TommyDel
TommyDel Apr. 9 at 6:34 PM
$PRFX buy whilst cheapies now. It’s got potential to go crazy!! Another $AIKI.X
0 · Reply
Weimanator
Weimanator Apr. 9 at 5:21 PM
$PRFX get ready to start, I see $18.00 coming
0 · Reply
xoin
xoin Apr. 9 at 3:45 PM
$PRFX start now
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Apr. 9 at 3:03 PM
$PRFX RSI: 50.85, MACD: -0.1636 Vol: 0.24, MA20: 2.31, MA50: 2.77 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
Zboquid
Zboquid Apr. 7 at 4:16 PM
$PRFX $2.40 pre 5 to 1 reverse split = $0.48 per
0 · Reply
TommyDel
TommyDel Apr. 7 at 3:22 PM
$PRFX low float! Volume hits. Can go very crazy
0 · Reply
TommyDel
TommyDel Apr. 7 at 3:22 PM
$PRFX she building for a run!!
0 · Reply
STACKD0E
STACKD0E Apr. 7 at 1:30 PM
$PFSA $CLIR $PRFX $ALHC $CETX
0 · Reply
Zboquid
Zboquid Apr. 7 at 12:36 PM
$PRFX Lame no news fake pump yesterday
0 · Reply
Stock_Catcher
Stock_Catcher Apr. 7 at 1:56 AM
Treasure Tuesday Watchlist Pt.7 $SKYQ $RENX $TLRY $UGRO $PRFX I will look for another 515%+ Runner
0 · Reply
RafaelTheOne
RafaelTheOne Apr. 7 at 1:16 AM
$PRFX
0 · Reply
Longislandbull
Longislandbull Apr. 6 at 9:48 PM
What an amazing day. $17K between $AIXI $FCUV $PRFX and $PFSA Exact levels and guidance given all day on AIKI Join our discord for a free trial today!! 👇 https://trifectatrading.tiiny.site/
0 · Reply